Rallybio公布Rlyb116一期研究积极数据,显示对末端补体完全且持续的抑制作用

美股速递
Feb 17

Rallybio Corp.(股票代码:RLYB)今日宣布其候选药物Rlyb116在一期临床研究中取得积极数据。研究结果显示,该药物能够实现对末端补体系统的完全抑制,且抑制作用持久稳定。这一突破性进展为后续开发针对补体介导疾病的创新疗法奠定了重要基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10